Drugs for Joint Laxity, Short Stature, and Myopia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 175)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Tropicamide |
Approved, Investigational |
Phase 4 |
|
1508-75-4 |
5593 |
Synonyms:
(+-)-N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide
1508-75-4
5-22-09-00359 (Beilstein Handbook Reference)
AB00052120
AC1L1KOZ
AC1Q5IFA
AC-816
Akorn brand OF tropicamide
Akorn Brand of Tropicamide
Alcon brand OF tropicamide
Alcon Brand of Tropicamide
AR-1K6980
Bio-0810
Bistropamide
Bournonville brand OF tropicamide
Bournonville Brand of Tropicamide
BPBio1_000303
BRD-A79672927-001-05-8
BRN 0285563
BSPBio_000275
BSPBio_002289
Cahill may roberts brand OF tropicamide
Cahill May Roberts Brand of Tropicamide
Chauvin brand OF tropicamide
Chauvin Brand of Tropicamide
CHEMBL1200604
CID5593
Colircusi tropicamida
Colircusi Tropicamida
CPD000058523
D00397
D014331
DB00809
DivK1c_000448
EINECS 216-140-2
Epitromina
EU-0101223
HMS1568N17
HMS1921I09
HMS2089M05
HMS2092A18
HMS501G10
I06-0811
IDI1_000448
I-Picamide
KBio1_000448
KBio2_001064
KBio2_003632
KBio2_006200
KBio3_001509
KBioGR_000873
KBioSS_001064
L001262
Lopac0_001223
LS-28545
Medical ophthalmics brand OF tropicamide
Medical Ophthalmics Brand of Tropicamide
Minims tropicamide
MLS001306442
MLS002154240
MolPort-000-159-321
Mydral
Mydriacyl
Mydriacyl (TN)
Mydriafair
Mydriaticum
Mydrum
NCGC00016065-03
NCGC00016065-08
NCGC00024866-02
NCGC00024866-03
NCGC00024866-04
NCGC00024866-05
NCGC00024866-06
N-Ethyl-2-phenyl-N-(4-pyridylmethyl)hydracrylamide
N-Ethyl-2-phenyl-N-4-[-pyridyl-methyl]hydracrylamide
N-ethyl-3-hydroxy-2-phenyl-N-(pyridin-4-ylmethyl)propanamide
N-Ethyl-alpha-(hydroxymethyl)-N-(4-pyridinylmethyl)benzeneacetamide
N-Ethyl-N-(4-pyridylmethyl)tropamid
N-Ethyl-N-(4-pyridylmethyl)tropamide
n-ethyl-n-(g-picolyl)tropamide
NINDS_000448
Novartis brand OF tropicamide
Novartis Brand of Tropicamide
|
Ocu tropic
Ocu Tropic
Ocumed brand OF tropicamide
Ocumed Brand of Tropicamide
Ocusoft brand OF tropicamide
Ocusoft Brand of Tropicamide
Ocu-tropic
OcuTropic
Ocu-Tropic
Opticyl
Paremyd
Pharmafair brand OF tropicamide
Pharmafair Brand of Tropicamide
Prestwick_487
Prestwick0_000228
Prestwick1_000228
Prestwick2_000228
Prestwick3_000228
Rivex brand OF tropicamide
Rivex Brand of Tropicamide
Ro 1-7683
SAM002564235
SMP1_000304
SMR000058523
SPBio_000872
SPBio_002196
Spectro-Cyl
Spectrum_000584
SPECTRUM1500599
Spectrum2_000936
Spectrum3_000655
Spectrum4_000377
Spectrum5_001585
STK934612
Stulln brand 1 OF tropicamide
Stulln Brand 1 of Tropicamide
Stulln brand 2 OF tropicamide
Stulln Brand 2 of Tropicamide
T 9778
T9778_SIGMA
TL8001101
Triaminic DM
Tropicacyl
Tropicamid
Tropicamida
Tropicamida [INN-Spanish]
tropicamide
Tropicamide
Tropicamide (JP15/USP/INN)
Tropicamide [USAN:INN:BANJAN]
Tropicamide alcon brand
Tropicamide Alcon Brand
Tropicamide chauvin brand
Tropicamide Chauvin Brand
Tropicamide faure
Tropicamide Faure
Tropicamide minims
Tropicamide Minims
Tropicamide monofree
Tropicamide Monofree
Tropicamide monohydrochloride, (R)-isomer
Tropicamide Monohydrochloride, (R)-Isomer
Tropicamide monohydrochloride, (S)-isomer
Tropicamide Monohydrochloride, (S)-Isomer
Tropicamide novartis brand
Tropicamide Novartis Brand
Tropicamide ocumed brand
Tropicamide Ocumed Brand
Tropicamide pharmafair brand
Tropicamide Pharmafair Brand
Tropicamide rivex brand
Tropicamide Rivex Brand
Tropicamide, (+-)-isomer
Tropicamide, (+-)-Isomer
Tropicamide, (R)-isomer
Tropicamide, (R)-Isomer
Tropicamide, (S)-isomer
Tropicamide, (S)-Isomer
Tropicamidum
Tropicamidum [INN-Latin]
Tropikamid
Tropimil
UNII-N0A3Z5XTC6
Visumidriatic
|
|
2 |
|
Fluorometholone |
Approved, Investigational |
Phase 4 |
|
426-13-1 |
9878 |
Synonyms:
(1R,2S,8S,10S,11S,14R,15S,17S)-14-acetyl-1-fluoro-14,17-dihydroxy-2,8,15-trimethyltetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-5-one
(6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11beta,17alpha-Dihydroxy-9-fluoro-6-methyl-1,4-pregnadiene-3,20-dione
426-13-1
9-Fluoro-11,17-dihydroxy-6-methylpregna-1,4-diene-3,20-dione
9-fluoro-11b,17-Dihydroxy-6a-methylpregna-1,4-diene-3,20-dione
9-fluoro-11beta,17-Dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,17-dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11-beta,17-dihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
9-fluoro-11β,17-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione
AC1L1U0Y
AC-3520
AI3-52813
Alcon brand OF fluorometholone
Alcon Brand of Fluorometholone
Allergan brand 1 OF fluorometholone
Allergan Brand 1 of Fluorometholone
Allergan brand 2 OF fluorometholone
Allergan Brand 2 of Fluorometholone
Allergan brand 3 OF fluorometholone
Allergan Brand 3 of Fluorometholone
BPBio1_001029
BRD-K64862097-001-03-9
BSPBio_000935
CHEMBL1200600
CID9878
component of Neo-Oxylone
Cortilet
Cortisdin
D005469
D01367
DB00324
Delmeson
Efflumidex
EINECS 207-041-5
F0414
F9381_SIGMA
Fluaton
Flucon
Flucon, isopto
Flucon, Isopto
Flumetholon
Fluor Op
Fluor OP
Fluormetholon
Fluormetholone
Fluormetholonum
fluoro Ophtal
Fluoro Ophtal
Fluoromethalone
Fluorometholon
fluorometholone
Fluorometholone
Fluorométholone
Fluorometholone (JP15/USP/INN)
Fluorometholone [INN:BAN:JAN]
Fluorometholonum
Fluorometholonum [INN-Latin]
Fluorometolona
Fluorometolona [INN-Spanish]
|
Fluorometolone
Fluorometolone [DCIT]
fluoro-Ophtal
Fluoro-Ophtal
Fluor-Op
Fluor-OP
Fluor-op (TN)
Fluoropos
FML
Fml (TN)
FML Forte
FML Liquifilm
FML S.O.P
FML-S Liquifilm
HMS1570O17
Isdin brand OF fluorometholone
Isdin Brand of Fluorometholone
isopto Flucon
Isopto Flucon
Loticort
LS-118455
MLS000069537
MLS001076157
MolPort-003-941-413
NCGC00021575-03
NCI60_002886
Neo-Oxylone
Novartis brand OF fluorometholone
Novartis Brand of Fluorometholone
NSC 33001
NSC33001
NSC-33001
Oxylone
Oxylone (TN)
Pharm allergan brand OF fluorometholone
Pharm Allergan Brand of Fluorometholone
Pharm-allergan brand OF fluorometholone
Pharm-Allergan Brand of Fluorometholone
Pharmascience brand OF fluorometholone
Pharmascience Brand of Fluorometholone
PMS Fluorometholone
PMS-Fluorometholone
Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,17-dihydroxy-6alpha-methyl- (8CI)
Prestwick_227
Prestwick0_000718
Prestwick1_000718
Prestwick2_000718
Prestwick3_000718
SMR000058598
SPBio_002856
Trilcin
U 8614
UNII-SV0CSG527L
Ursapharm brand OF fluorometholone
Ursapharm Brand of Fluorometholone
Ursnon
Winzer brand OF fluorometholone
Winzer Brand of Fluorometholone
ZINC03876158
|
|
3 |
|
Loteprednol |
Approved, Experimental |
Phase 4 |
|
129260-79-3, 82034-46-6 |
9865442 444025 |
Synonyms:
17-Ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate, chloromethyl
82034-46-6
AC1L9FKJ
AKOS005145741
Alrex
Alrex, Lotemax, Loteprednol etabonate
CDDD-5604
CEHOAC
CHEBI:31784
CHEMBL1200865
chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
Chloromethyl 17 ethoxycarbonyloxy 11 hydroxy 3 oxoandrosta 1,4 diene 17 carboxylate
chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate
Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate
CID444025
CPD000469178
D01689
DB00873
Etabonate, loteprednol
HGP-1
|
HMS2051F16
IDR-90102
IDR-90103
Locort
Loteflam
Lotemax
Lotemax (TN)
Loteprednol
Loteprednol etabonate
Loteprednol etabonate (JAN/USAN)
Loterox
MLS001424221
MolPort-003-848-424
NCGC00164594-01
P-5604
S1669_Selleck
SAM001246630
SMR000469178
ZINC03920673
|
|
4 |
|
Ketorolac |
Approved |
Phase 4 |
|
66635-83-4, 74103-06-3 |
3826 |
Synonyms:
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-isomer
(+-)-Ketorolac
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC1L1GSW
AC-545
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
I14-2832
Ketoralac
|
ketorolac
Ketorolac
Kétorolac
Ketorolac (INN)
Ketorolac [INN:BAN]
Ketorolac tromethamine
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
rac-Ketorolac
RS 37619
RS-37619
SBB067312
STL018674
Toradol
Toradol (TN)
UNII-YZI5105V0L
|
|
5 |
|
Ranibizumab |
Approved |
Phase 4 |
|
347396-82-1 |
459903 |
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
ranibizumab
|
Ranibizumab
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
Ranibizumab (USAN/INN)
rhuFab V2
|
|
6 |
|
Nepafenac |
Approved, Investigational |
Phase 4 |
|
78281-72-8 |
151075 |
Synonyms:
2-amino-3-benzoylbenzeneacetamide
2-amino-3-Benzoylbenzeneacetamide
AHR 9434
AHR-9434
AL 6515
AL-6515
|
Amfenac amide
Nepafenac
Népafénac
Nepafenaco
Nepafenacum
Nevanac
|
|
7 |
|
Hydrogen peroxide |
Approved, Vet_approved |
Phase 4 |
|
7722-84-1 |
784 |
Synonyms:
[OH(OH)]
Adeka super el
Albone
Albone 35
Albone DS
Anti-keim 50
Asepticper
Baquashock
CIX
Clarigel gold
Crestal whitestrips
Crystacide
Dentasept
Deslime LP
Dihydrogen dioxide
H2O2
Hioxyl
Hipox
HOOH
Hybrite
Hydrogen dioxide
Hydrogen peroxide (H2O2)
Hydroperoxide
Inhibine
Lase peroxide
|
Lensan a
Magic bleaching
Metrokur
Mirasept
Nite white excel 2
Odosat D
Opalescence xtra
Oxigenal
Oxydol
Oxyfull
Oxysept
Oxysept I
Pegasyl
Perhydrol
Perone
Peroxaan
Peroxclean
Peroxide, hydrogen
Quasar brite
Select bleach
Superoxol
T-Stuff
Whiteness HP
Whitespeed
Xtra white
|
|
8 |
|
Polihexanide |
Approved, Investigational |
Phase 4 |
|
28757-47-3 |
|
Synonyms:
Polyhexamethylene biguanide
|
|
|
9 |
|
Levofloxacin |
Approved, Investigational |
Phase 4 |
|
100986-85-4 |
149096 |
Synonyms:
(−
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-Ofloxacin
(3S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylate
(3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
(R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(R)-isomer
(S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylate
(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-Ofloxacin
(S)-9-fluoro-2,3-dihydro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylate
(S)-9-fluoro-2,3-dihydro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
)-Ofloxacin
100986-85-4
100986-86-5
28266_FLUKA
28266_SIGMA
AC1L3YF8
AC-7593
Aeroquin
Ambap100986-85-4
Anhydrous, levofloxacin
BRD-K09471561-001-06-7
BSPBio_002689
C07660
C18H20FN3O4
C18H20FN3O4.H2O
CCRIS 4073
CCRIS 4074
CHEMBL33
CID149096
CPD000466387
Cravit
Cravit (TN)
Cravit Ophthalmic
D08120
DB01137
d-Levofloxacin
DR 3354
DR3355
DR-3355
DR-3355: L-isomer of ofloxacin
Elequine
Floxacin
Floxel
Floxin
HMS1922J07
HMS2051G04
HMS2090O10
HMS2093E18
HR 355
HR-355
Iquix
KBio2_002199
|
KBio2_004767
KBio2_007335
KBio3_001909
KBioGR_001605
KBioSS_002199
L0193
Leroxacin
Lesacin
Levaquin
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Levofloxacin
LEVOFLOXACIN
Levofloxacin (INN)
Levofloxacin [USAN:INN:JAN]
Levofloxacin anhydrous
Levofloxacin hydrate
Levofloxacin tablet, suspension or intravenous
Levofloxacine
Levofloxacine [INN-French]
Levofloxacino
Levofloxacino [INN-Spanish]
Levofloxacinum
Levofloxacinum [INN-Latin]
Levokacin
Levox
Levoxacin
LFX
L-Ofloxacin
LS-133260
LS-171761
LVX
MLS000759524
MLS001165709
MLS001423977
MolPort-002-885-835
Mosardal
MP-376
NCGC00178529-01
Nofaxin
Ofloxacin
Ofloxacin S-(-)-form
Ofloxacin, (S)-isomer
Oftaquix
Quixin
Reskuin
R-Ofloxacin
RWJ 25213-097
RWJ-25213
S-(-)-Ofloxacin
S1940_Selleck
SAM001246758
SMR000466387
SPBio_001891
Spectrum_001719
SPECTRUM1504260
Spectrum2_001676
Spectrum3_000995
Spectrum4_001123
Spectrum5_001438
Tavanic
Volequin
|
|
10 |
|
Ofloxacin |
Approved |
Phase 4 |
|
82419-36-1 |
4583 |
Synonyms:
( -)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure
(+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- -oxo-7H-pyrido(1,2,3-de)- -1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
(+/-)-Floxin
118120-51-7 (hydrochloride)
33703_FLUKA
33703_RIEDEL
82419-36-1
83380-47-6
85344-55-4
8-fluoro-3-Methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylate
8-fluoro-3-Methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
AB00513820
AC1L1IHM
AC-7616
Akilen
AKOS001033517
Baccidal
Bactocin
BB_SC-1252
BPBio1_000345
BRD-A24228527-001-05-9
BRN 3657947
BSPBio_000313
BSPBio_003117
C07321
C18H20FN3O4
CCRIS 5233
CHEBI:7731
CHEMBL4
CID4583
CPD000058192
D00453
Danoflox
DB01165
DEXTROFLOXACINE
DivK1c_000721
DL 8280
DL-8280
DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin
Effexin
EU-0100904
Exocin
Exocine
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
Floxin (TN)
FLOXIN IN DEXTROSE 5%
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Floxin otic
Floxstat
Fugacin
HMS1568P15
HMS1921H12
HMS2090F07
HMS2092B10
HMS502E03
Hoe 280
HOE 280
Hoe-280
I06-0112
I06-0380
IDI1_000721
Inoflox
KBio1_000721
KBio2_001666
KBio2_004234
KBio2_006802
KBio3_002617
KBioGR_000667
KBioSS_001666
Kinflocin
Kinoxacin
Liflox
Lopac0_000904
Loxinter
LS-133259
Marfloxacin
Medofloxine
Mergexin
MLS000028749
MLS001074203
MolPort-000-422-241
MolPort-000-873-068
NCGC00015772-02
NCGC00015772-10
|
NCGC00094219-01
NCGC00094219-02
NCGC00094219-03
NCGC00094219-04
NCGC00094219-05
NCGC00094219-06
NCGC00178284-01
NCGC00178284-02
NINDS_000721
Novecin
NSC727071
Nufafloqo
O 8757
O8757_SIGMA
Obide
Occidal
Ocuflox
Ofcin
Oflin
Oflocee
Oflocet
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
O-Flox
ofloxacin
Ofloxacin
Ofloxacin (JP15/USP/INN)
Ofloxacin [USAN:BAN:INN:JAN]
Ofloxacin hydrochloride
Ofloxacin Otic
Ofloxacin, (S)-Isomer
Ofloxacina
Ofloxacina [DCIT]
Ofloxacine
Ofloxacine [French]
Ofloxacino
Ofloxacino [Spanish]
Ofloxacinum
Ofloxacinum [Latin]
Ofloxin
OFLX
Ofus
OFX
Onexacin
Operan
Oprea1_242882
ORF 18489
ORF-28489
Orocin
Otonil
Oxaldin
Pharflox
Praxin
Prestwick0_000237
Prestwick1_000237
Prestwick2_000237
Prestwick3_000237
PT 01
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Ru-43280
S1463_Selleck
SAM002264629
Sinflo
SMR000058192
SPBio_001387
SPBio_002234
Spectrum_001186
SPECTRUM1502044
Spectrum2_001464
Spectrum3_001499
Spectrum4_000324
Spectrum5_001063
STK256723
Tabrin
Taravid
Tariflox
Tarivid
Telbit
Tructum
UNII-A4P49JAZ9H
Uro Tarivid
Viotisone
Visiren
WP-0405
XED
Zanocin
|
|
11 |
|
Lactitol |
Approved, Investigational |
Phase 4 |
|
585-88-6, 585-86-4 |
493591 |
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
Lactitol
Lactitolum
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
12 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(diethylamino)-2',6'-Acetoxylidide
2-(Diethylamino)-2',6'-acetoxylidide
2-(diethylamino)-N-(2,6-Dimethylphenyl)acetamide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-diethylamino-2,6-Dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-Dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
Leostesin
|
Lida-Mantle
Lidocaina
Lidocaína
Lidocaina [INN-Spanish]
lidocaine
Lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
13 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(±)-bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
15233-43-9
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
2180-92-9
38396-39-3
AB00053674
Abbott brand OF bupivacaine hydrochloride
AC1L1DRE
AC1Q5LX4
AC-2096
AH 250
AKOS001637202
Anekain
Anhydrous, bupivacaine
AR-1A0242
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bio-0886
Bloqueina
BPBio1_000298
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bucaine
Bucaine (TN)
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
bupivacaine
Bupivacaine
Bupivacaine (INN)
Bupivacaine [INN:BAN]
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine HCL KIT
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacaine Monohydrochloride, Monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
C07529
C18H28N2O
Carbonate, bupivacaine
Carbostesin
cBupivacaine
CBupivacaine
CHEBI:3215
|
CHEMBL1098
CID2474
D07552
DB00297
DepoBupivacaine
DivK1c_000758
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
Dolanaest
DUR-843
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
Hydrochloride, bupivacaine
IDI1_000758
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MLS001361336
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Pisa brand OF bupivacaine hydrochloride
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SMR000058218
SPBio_001558
SPBio_002489
Spectrum_001524
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
|
|
14 |
|
Atracurium |
Approved, Experimental, Investigational |
Phase 4 |
|
64228-79-1 |
47319 |
Synonyms:
1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
64228-79-1
64228-81-5 (besylate)
AB00514743
AC1L2HUF
AC1Q67HR
Atracurium
Atracurium besilate
Atracurium besylate
Atracurium dibesylate
Atracurium Dibesylate
Besilate, atracurium
BPBio1_000011
BRN 1523633
BSPBio_000009
BW 33a
BW33a
BW-33a
|
C07548
C53H70N2O12
CHEBI:2914
CHEMBL1360
CID47319
DB00732
glaxo Wellcome brand OF atracurium besilate
HMS2090I21
LS-86151
MolPort-005-932-641
Pisa brand OF atracurium besilate
Prestwick1_000005
Prestwick2_000005
Prestwick3_000005
Relatrac
SPBio_001930
Tracrium
UNII-2GQ1IRY63P
Wellcome brand OF atracurium besilate
|
|
15 |
|
Dipivefrin |
Approved |
Phase 4 |
|
52365-63-6 |
3105 |
Synonyms:
( -)-2,2-Dimethylpropansaeure-4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylenester
( -)-4-(1-Hydroxy-2-methylaminoethyl)-o-phenylendipivalat
(+-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol 3,4-dipivalate
(+-)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
(+-)-4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
(±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
(RS)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat
[2-(2,2-dimethylpropanoyloxy)-4-[1-hydroxy-2-(methylamino)ethyl]phenyl] 2,2-dimethylpropanoate
1-(3',4'-dipivaloyloxyphenyl)-2-methylamino-1-ethanol
1-(3',4'-Dipivaloyloxyphenyl)-2-methylamino-1-ethanol
2,2-Dimethylpropanoic acid 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylen dipivalat
4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diyl bis(2,2-dimethylpropanoate)
4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalate
4-[1-Hydroxy-2-(methylamino)ethyl]-O-phenylene divavalic acid
52365-63-6
AB00514686
AC1L1F6K
Adrenaline dipivalate
AKOS003662293
AKPro
Alcon brand OF dipivefrin hydrochloride
Allergan brand OF dipivefrin hydrochloride
apo-Dipivefrin
Apotex brand OF dipivefrin hydrochloride
BPBio1_000688
BRD-A47494775-003-03-0
BSPBio_000624
C06963
C19H29NO5
CHEBI:4646
CID3105
D Epifrin
D02349
DB00449
Diopine
Dipivaloylepinephrine
dipivalyl epinephrine
Dipivalyl epinephrine
dipivefrin
Dipivefrin
Dipivefrin (USAN)
|
Dipivefrin [USAN]
Dipivefrin acetate, (+-)-isomer
Dipivefrin citrate (1:1), (+-)-isomer
Dipivefrin HCL
Dipivefrin hydrochloride
Dipivefrin hydrochloride, (+-)-isomer
Dipivefrin monophosphate, (+-)-isomer
Dipivefrin monosulfate, (+-)-isomer
Dipivefrin nitrate, (+-)-isomer
Dipivefrin perchlorate
Dipivefrin propanoate, (+-)-isomer
Dipivefrin tartrate (1:1), (+-)-(R-(r*,r*))-isomer
Dipivefrin tartrate (1:1), (R)-(R-(r*,r*))-isomer
Dipivefrin, (R)-isomer
Dipivefrina
Dipivefrina [INN-Spanish]
Dipivefrine
Dipivéfrine
Dipivefrine (INN)
Dipivefrinum
Dipivefrinum [INN-Latin]
Dipoquin
Glaucothil
Glaudrops
Ioquin brand OF dipivefrin hydrochloride
K 30081
L000915
LS-121419
NCGC00179499-01
nchembio747-comp3
Ophtho-Dipivefrin
Pharm-allergan brand OF dipivefrin hydrochloride
Pharmascience brand OF dipivefrin hydrochloride
PMS-Dipivefrin
Prestwick0_000632
Prestwick1_000632
Prestwick2_000632
Prestwick3_000632
Propine
Propine C Cap B.I.D.
ratio-Dipivefrin
Ratiopharm brand OF dipivefrin hydrochloride
SPBio_002843
UNII-8Q1PVL543G
|
|
16 |
|
Propoxycaine |
Approved |
Phase 4 |
|
86-43-1 |
|
17 |
|
Laxatives |
|
Phase 4 |
|
|
|
18 |
|
Cathartics |
|
Phase 4 |
|
|
|
19 |
|
Echothiophate Iodide |
|
Phase 4 |
|
6736-03-4 |
10547 |
Synonyms:
(2-Mercaptoethyl)trimethylammonium iodide S-ester with O,O-diethyl phosphorothioate
(2-mercaptoethyl)trimethylammonium iodidie O,O-diethyl phosphorothioate
2-((Diethoxyphosphinyl)thio)-N,N,N,-trimethylethanaminium iodide
2-[(diethoxyphosphinyl)thio]-N,N,N-trimethylethanaminium iodide
2-[(diethoxyphosphoryl)sulfanyl]-N,N,N-trimethylethanaminium iodide
2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide
217 MI
217-mi
2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid
2-Diaethoxyphosphinyl-thioaethyl-trimethyl-ammonium-jodid [German]
2-Diethoxy-phosphinylthioethyl-trimethylammonium iodide
2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium iodide
513-10-0
AC1L1VFJ
AC1Q1TM0
Ammonium, (2-(O,O-diethylphosphorothio)ethyl)trimethyl-, iodide
Ammonium, (2-mercaptoethyl)trimethyl-, iodide, S-ester with O,O-diethylphosphorothioate
C9H22NO3PS
CHEBI:59849
CHEMBL1200367
CID10547
D004456
D02193
DB01057
diethoxyphosphinylthiocholine iodide
Diethoxyphosphoryl-thiocholine iodide
Echodide
Echothiophate iodide
Echothiophate iodide (USP)
Ecostigmini jodidum
|
ECOTHIOPATE IODIDE
Ecothiopate iodide (JP15/INN)
Ecothiopati iodidum
Ecothiopati iodidum [INN-Latin]
Ecothiophate iodide
EINECS 208-152-1
Ethanaminium, 2-((diethoxyphosphinyl)thio)-N,N,N-trimethyl-, iodide
Iodide, Echothiophate
Iodide, Ecothiopate
Iodide, Ecothiophate
Iodide, Phospholine
Iodure d'ecothiopate
Iodure d'ecothiopate [INN-French]
Ioduro de ecotiopato
Ioduro de ecotiopato [INN-Spanish]
LS-18625
MolPort-005-941-436
N-(2-(Diethoxyphosphinylthio)ethyl)trimethylammonium iodide
O,O-Diethyl S-2-trimethylammonium ethylphosphonothiolate iodide
Phospholine
Phospholine (the pharmaceutical)
Phospholine iodide
Phospholine iodide (TN)
S-(2-(N,N,N-Trimethylammonio)ethyl) O,O-diethylphosphorothiolate iodide
S-(2-dimethylaminoethyl)-O,O-diethylphosphorothioate methiodide
S-(2-Dimethylaminoethyl)-O.O-diethylphosphorothioate methiodide
S-beta-dimethylaminoethyl-O,O-diethylthionophosphate methiodide
S-Ester of (2-mercaptoethyl)trimethylammonium iodide with O,O-diethyl phosphorothioate
UNII-BA9QH3P00T
|
|
20 |
|
Carboxymethylcellulose Sodium |
|
Phase 4 |
|
|
|
21 |
|
Cholinesterase Inhibitors |
|
Phase 4 |
|
|
|
22 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
23 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
24 |
|
Lubricant Eye Drops |
|
Phase 4 |
|
|
|
25 |
|
Mitomycins |
|
Phase 4 |
|
|
|
26 |
|
Alkylating Agents |
|
Phase 4 |
|
|
|
27 |
|
Angiogenesis Inhibitors |
|
Phase 4 |
|
|
|
28 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
29 |
|
Analgesics |
|
Phase 4 |
|
|
|
30 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
31 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
32 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
33 |
|
Biguanides |
|
Phase 4 |
|
|
|
34 |
|
Ketorolac Tromethamine |
|
Phase 4 |
|
|
|
35 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
36 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
37 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
38 |
|
Neuromuscular Blocking Agents |
|
Phase 4 |
|
|
|
39 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
40 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
41 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
42 |
|
Parasympatholytics |
|
Phase 4 |
|
|
|
43 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
44 |
|
Muscarinic Antagonists |
|
Phase 4 |
|
|
|
45 |
|
Mydriatics |
|
Phase 4 |
|
|
|
46 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
47 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
48 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
49 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
50 |
|
Anesthetics |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 695)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Echothiophate Iodide for the Prevention of Progression of Myopia |
Unknown status |
NCT02544529 |
Phase 4 |
Echothiophate Iodide 0.03% Ophthalmic Solution;Carboxymethylcellulose Sodium (0.5%) |
2 |
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK |
Unknown status |
NCT02071576 |
Phase 4 |
|
3 |
Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine |
Unknown status |
NCT00541177 |
Phase 4 |
atropine;tropicamide |
4 |
A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK |
Unknown status |
NCT01977807 |
Phase 4 |
|
5 |
Ranibizumabe Intravitreal Injection for Myopic Choroidal Neovascularization |
Unknown status |
NCT01246089 |
Phase 4 |
ranibizumab injection |
6 |
A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia |
Unknown status |
NCT02112968 |
Phase 4 |
|
7 |
A Prospective, Randomized, Multi Center Clinical Comparison Of Fellow Eyes Undergoing Lasik Using The Amo/Visx Customvue™ , The Bausch And Lomb Zyoptix And Planoscan And The Wavelight Allegretto Wave™ Wavefront Guided And Wavefront Optimized Excimer Laser Systems |
Unknown status |
NCT00770094 |
Phase 4 |
|
8 |
Comparison of Next Generation Laser Techniques of Myopia Correction: iDesign vs. SMILE |
Unknown status |
NCT03001401 |
Phase 4 |
|
9 |
Randomized, Single Blinded Controlled Trial for Evaluation of the Safety and Efficacy of Loteprednol Versus Fluorometholone After Photorefractive Keratectomy for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study |
Unknown status |
NCT02974387 |
Phase 4 |
Fluorometholone(FML);Loteprednol (Lotemax) |
10 |
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization |
Unknown status |
NCT02033018 |
Phase 4 |
Aflibercept Injection |
11 |
Effect of Orthokeratology on Myopia Progression in Chinese Children |
Completed |
NCT02186184 |
Phase 4 |
|
12 |
A Prospective, Randomised Trial of Photo-Refractive Keratectomy (PRK) and Laser-in-Situ-Keratomileusis (LASIK) for Correction of Myopia |
Completed |
NCT00404105 |
Phase 4 |
|
13 |
Effects of Contact Lens Care Regimens on the Corneal Epithelium |
Completed |
NCT00349882 |
Phase 4 |
Marketed multipurpose disinfection regimen |
14 |
Evaluation of Stenfilcon A Versus Etafilcon A |
Completed |
NCT01809834 |
Phase 4 |
|
15 |
Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds |
Completed |
NCT00564213 |
Phase 4 |
PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds |
16 |
A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap |
Completed |
NCT01693939 |
Phase 4 |
|
17 |
Investigation of Multi-Purpose Solution-Based Corneal Staining and Ocular Comfort With Daily Wear FDA Group IV Hydrogel Lenses |
Completed |
NCT00349843 |
Phase 4 |
Marketed soft lens multipurpose disinfection regimen |
18 |
A Prospective Evaluation of Outcomes Following Wavefront Optimized or Wavefront Guided Lasik Procedure in Low to Moderate Myopic Patients |
Completed |
NCT01173198 |
Phase 4 |
|
19 |
Clinical Comfort Evaluation of Biofinity and Acuvue Oasys Lenses |
Completed |
NCT01695369 |
Phase 4 |
|
20 |
Product Performance of Bausch & Lomb PureVision® Contact Lens When Compared to Johnson & Johnson Acuvue Oasys Contact Lens and the Ciba Vision O2Optix Contact Lens Worn Daily. |
Completed |
NCT00640341 |
Phase 4 |
|
21 |
Clinical Study of Approved Contact Lenses |
Completed |
NCT03351101 |
Phase 4 |
|
22 |
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization |
Completed |
NCT00797992 |
Phase 4 |
Injection |
23 |
A Prospective Study to Evaluate the Safety and Effectiveness of the Supracor Presbyopic Treatment Algorithm for Pseudophakic Eyes Using Lasik |
Completed |
NCT01387360 |
Phase 4 |
|
24 |
Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK |
Completed |
NCT00889941 |
Phase 4 |
|
25 |
Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist |
Completed |
NCT02024698 |
Phase 4 |
|
26 |
Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser |
Completed |
NCT01746589 |
Phase 4 |
|
27 |
BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study |
Completed |
NCT02537730 |
Phase 4 |
|
28 |
Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision |
Completed |
NCT00627302 |
Phase 4 |
PEG-400;Systane |
29 |
Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses |
Completed |
NCT01707238 |
Phase 4 |
|
30 |
Daily Disposable Comparison Study |
Completed |
NCT02094677 |
Phase 4 |
|
31 |
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia |
Completed |
NCT03409250 |
Phase 4 |
Ranibizumab, Lucentis |
32 |
Long-term Effects of Laser Refractive Surgery |
Completed |
NCT00350246 |
Phase 4 |
|
33 |
Clinical Performance of Stenfilcon A Versus Filcon II 3 |
Completed |
NCT01808209 |
Phase 4 |
|
34 |
A Prospective, Multi Center Clinical Comparison of Fellow Eyes Undergoing Lasik Using the Wavelight Allegretto Wave™ Excimer Laser in One Eye and the Amo/Visx Customvue™ or the Ladarvision 4000 Excimer Laser System in the Contralateral Eye |
Completed |
NCT00821236 |
Phase 4 |
|
35 |
The Influence of Atropine on Choroidal Thickness |
Completed |
NCT03158142 |
Phase 4 |
Atropine Sulfate 1% Oph Soln |
36 |
The Effects of Low Dose Atropine on Choroidal Thickness |
Completed |
NCT03544827 |
Phase 4 |
Atropine;Atropine |
37 |
Single-Center Clinical Evaluation of Daily Disposable Contact Lenses |
Completed |
NCT02097030 |
Phase 4 |
|
38 |
Infiltrative Events During Silicone Hydrogel Daily Contact Lens (Daily Wear Corneal Infiltrative Event (DWCIE) Study) |
Completed |
NCT00937105 |
Phase 4 |
|
39 |
Corneal and Conjunctival Sensitivity and Staining Study |
Completed |
NCT00455455 |
Phase 4 |
Optifree RepleniSH Multipurpose Disinfecting Solution;ReNu Multiplus Multipurpose Solution |
40 |
Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study |
Completed |
NCT03042871 |
Phase 4 |
0.5mg intravitreal ranibizumab |
41 |
Effect of Contact Lens Wear on Immune Cell Density and Morphology of the Ocular Surface: A Laser In Vivo Confocal Microscopy Study |
Completed |
NCT01250925 |
Phase 4 |
ReNu MultiPlus® MultiPurpose Solution;OPTI-FREE® RepleniSH®;Clear Care® |
42 |
Double Masked Evaluation of Acular LS Versus Nevanac for Postoperative Pain Control in Eyes Undergoing PRK |
Completed |
NCT00347204 |
Phase 4 |
ketorolac (Acular LS);Nepafenac (Nevanac) |
43 |
Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab |
Completed |
NCT02309281 |
Phase 4 |
aflibercept 2mg |
44 |
Efficacy and Safety of Low Dose Atracurium Added to Lidocaine, Bupivacaine and Hyaluronidase Mixture in Percaruncular Peribulbar Anesthesia for High Myopes Undergoing Phacoemulsification: A Randomized Controlled Trial. |
Completed |
NCT03243500 |
Phase 4 |
Atracurium;Lidocaine 2%;Bupivacaine 0.5%;hyaluronidase powder |
45 |
Clinical Investigation of the Vision-R800 Device. Understanding the Value of High Precision Refractions and Lenses to Optometrists and Patients. Phase 2 |
Recruiting |
NCT04208750 |
Phase 4 |
|
46 |
A Prospective, Randomized Comparison of SMILE Surgery to Wavefront-guided LASIK Surgery |
Active, not recruiting |
NCT03067077 |
Phase 4 |
|
47 |
A Prospective Eye to Eye Comparison of LASIK Using the Alcon Allegretto Wavefront-Guided Excimer Laser Versus AMO Visx Wavefront-Guided Excimer Laser |
Active, not recruiting |
NCT01454843 |
Phase 4 |
|
48 |
Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain |
Active, not recruiting |
NCT01592643 |
Phase 4 |
|
49 |
A Prospective Randomized Eye to Eye Comparison of Fellow Eyes Undergoing Lasik With the IntraLase(TM) FS Versus PRK |
Active, not recruiting |
NCT01140594 |
Phase 4 |
|
50 |
A Prospective, Randomized Comparison of Fellow Eyes Undergoing Wavefront-guided PRK Versus Wavefront-optimized PRK Using the Alcon Allegretto Eye-Q 400 Excimer Laser |
Active, not recruiting |
NCT02091934 |
Phase 4 |
|
Cochrane evidence based reviews: myopia
|